Newborn screening testing services for bdaach, korea. FY24 task order for the base period, 29 SEP 2024 - 28 SEP 2025.
Ended Awarded Last action
- Contract number
- W81K0224F0135
- Awardee
-
Revvity Omics Inc. UEI LDJULX8K6M85 Part of Revvity Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $40,946
Award facts
- Opportunity
-
- Newborn Screening Testing Services for Brian D. Allgood Army Community Hospital (BDAACH), USAMEDDAC-Korea Pre-Solicitation · W81K0224Q0099 · Posted Jul 11, 2024
- Contract value 100% obligated
- $40,945.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- South Korea
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $40,945.50 firm fixed-price delivery order to Revvity Omics Inc. (doing business as Perkinelmer Genetics) on September 29, 2024, for newborn screening testing services at Brian D. Allgood Army Community Hospital (BDAACH) in South Korea. This task order covers the base performance period from September 29, 2024, through September 28, 2025, and was awarded without a small business set-aside designation. The delivery order is issued under a larger single-award indefinite delivery contract vehicle valued at $301,668 with a performance period extending through September 2029, which provides the Defense Health Agency with a strategic, long-term arrangement for comprehensive newborn screening services at the facility.
Revvity Omics Inc., a subsidiary of Revvity Inc., specializes in genetic and metabolic screening services for military healthcare systems. The company's newborn screening capabilities encompass detection of various conditions including galactosemia, hypothyroidism, cystic fibrosis, glucose-6-phosphate dehydrogenase deficiency, and hemoglobinopathies. This contract award reflects the contractor's established track record of providing laboratory analysis services to military treatment facilities across multiple international locations, supporting early detection and preventative medical care initiatives within the Defense Health Agency's healthcare network.
Quick answers
Who was awarded contract W81K0224F0135?
W81K0224F0135 was awarded to Revvity Omics Inc. by Medical Command (Department of the Army) on September 29, 2024.
How much is contract W81K0224F0135 worth?
The government has obligated $40,946 on W81K0224F0135.
Which agency awarded contract W81K0224F0135?
Medical Command (Department of the Army) awarded W81K0224F0135, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0224F0135 an order under another contract?
Yes. W81K0224F0135 is a delivery order under W81K0224D0009, an indefinite delivery contract.
Was contract W81K0224F0135 competed?
The extent of competition for W81K0224F0135 was competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award